Kidney disease does not automatically rule out tirzepatide. The Zepbound and Mounjaro labels call for no dose adjustment just because kidney function is reduced. But vomiting or diarrhea can cause dehydration and sudden kidney injury. Studies have also found encouraging kidney results, which do not promise the same outcome for one person.
The practical answer about tirzepatide and kidney disease is that both the starting kidney function and what happens during treatment matter. A dose that the body can process still needs a plan for side effects.
Tirzepatide and kidney disease: what the labels say
As of September 10, 2026, the day this article was written, the current Zepbound label and Mounjaro label both carry “Revised: 8/2026.” Section 8.6 of each recommends no kidney-based dose adjustment, including in kidney failure. Both also retain the warning about kidney injury from fluid loss.
The dosing evidence includes a small 2021 study of 45 people with different levels of kidney function. Eight needed dialysis, treatment that filters the blood when kidneys cannot. After one tirzepatide dose, kidney impairment did not meaningfully change drug exposure, the amount of medicine circulating over time (Urva et al., Clinical Pharmacokinetics, 2021).
That helps explain the label. It does not establish long-term safety for everyone on dialysis. The prescriber sets the actual dose and pace.
Can tirzepatide cause kidney injury?
Yes. Acute kidney injury means a sudden drop in kidney function. The labels describe reports after treatment reached the market, including cases needing dialysis. Most followed nausea, vomiting or diarrhea that left the person dehydrated. Monitoring matters especially when treatment starts or the dose rises.
Dehydration is not the only possible explanation. A case report published May 5, 2026, in JCEM Case Reports described interstitial nephritis, inflammation within kidney tissue, considered likely related to tirzepatide. A biopsy, a small tissue sample, confirmed the inflammation. One report cannot establish how often this happens or prove causation, but it makes “kidney injury is always dehydration” too strong.
Persistent vomiting or inability to keep fluids down warrants prompt medical assessment. The broader tirzepatide side-effects guide covers the usual stomach symptoms; worsening kidney tests need their own explanation.
What SURPASS-4 found about kidney function
The early signal came from SURPASS-4, a trial of 2,002 adults with type 2 diabetes and high heart risk. Its kidney report was a post-hoc analysis, an additional look at data from an existing trial (Heerspink et al., The Lancet Diabetes & Endocrinology, 2022).
Researchers tracked eGFR, a blood-test estimate of how well the kidneys filter. Over a median 85 weeks, its annual decline averaged 1.4 points with tirzepatide versus 3.6 with insulin glargine, a long-acting insulin. The exact units were mL/min/1.73 m²: filtering speed adjusted for body size.
They also measured albuminuria, leakage of the blood protein albumin into urine. Creatinine is a waste product; comparing urine albumin with it adjusts for urine concentration. That ratio fell 6.8% with tirzepatide while rising 36.9% with insulin; the reported between-group difference was −31.9%.
These findings support studying tirzepatide for kidney outcomes. They do not show that established kidney damage disappears.
What the 2026 kidney evidence adds
As of September 10, 2026, the day this article was written, a larger analysis had appeared in the July 2026 issue of The Lancet Diabetes & Endocrinology, published online May 11. It examined kidney outcomes in SURPASS-CVOT, a heart trial involving adults with type 2 diabetes and established artery disease.
Over about four years, roughly 6 in 100 tirzepatide participants had one of the counted kidney outcomes, versus about 8 in 100 receiving dulaglutide, another diabetes injection. The exact rates were 6.0% and 7.6%; the reported relative risk reduction was 23%.
That combined count included persistent high urine protein, a lasting halving of filtering capacity, kidney failure or kidney-related death. It was a planned exploratory analysis, meaning a question specified in advance but outside the trial's main test. It adds evidence beyond SURPASS-4 without proving a benefit for every kidney condition.
Semaglutide's FLOW trial, NEJM 2024, was designed around kidney outcomes; semaglutide and kidney disease explains that separate evidence.
What about people without diabetes?
A SURMOUNT-1 analysis first published March 8, 2026, in Diabetes, Obesity and Metabolism followed 1,032 participants with obesity or overweight and prediabetes, blood sugar above normal but below the diabetes range, for 176 weeks.
Their kidney function was mostly preserved at the start. Using creatinine and cystatin C, another blood marker used to estimate filtering, researchers found an average eGFR of 95.3 with tirzepatide versus 91.6 with placebo, a comparison treatment without active drug. That was a 3.7-point difference.
The authors caution that this additional analysis had substantial missing data. It is a reason for further study, not a result that transfers directly to someone with advanced kidney disease.
Has TREASURE-CKD reported results?
As of September 10, 2026, the day this article was written, TREASURE-CKD, NCT05536804, was listed as “Active, not recruiting,” with “No Results Posted.” The record's last update was May 8, 2026. Its estimated primary completion was September 2026 and study completion October 2026; those are estimates, not announcements of results.
This smaller phase 2 study, an earlier stage of clinical testing, plans about 140 participants with kidney disease and overweight or obesity, with or without diabetes. The current main measurement is change in fat around the kidney's central structures using MRI, a scan made with magnets. Filtering and urine protein are also measured over 52 weeks. Enrollment being finished does not mean the study has answered its question.
What a provider asks before prescribing
The useful starting point is recent kidney testing and the pattern over time. Baseline creatinine and eGFR provide a comparison if later tests change. Urine protein adds information that filtering estimates alone can miss.
A provider also reviews diuretics, medicines that increase urine output, and ACE inhibitors or ARBs, blood-pressure medicines often used in kidney care. Prior dehydration, vomiting, low-pressure episodes and any fluid restriction help shape follow-up. The medication list is a reason to coordinate care, not a reason to change those medicines independently.
What a compounded prescription means here
Through Promise, tirzepatide is dispensed as a compounded medication, prepared by a pharmacy for a prescription, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. The FDA explains that compounded drugs do not undergo its premarket review; that remains the distinction as of September 10, 2026. These trials did not test Promise's formulation.
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor. At Promise, a licensed provider reviews every request, and not everyone qualifies. Kidney history belongs in that review before a prescription is considered.